Page last updated: 2024-08-17
quinoline and tas-116
quinoline has been researched along with tas-116 in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chong, KT; Funabashi, K; Kawai, Y; Kitade, M; Kodama, Y; Mizutani, T; Muraoka, H; Ohkubo, M; Ohkubo, S; Oshiumi, H; Shigeno, K; Suzuki, T; Takahashi, K; Uno, T; Yamashita, S; Yoshimura, C | 1 |
Other Studies
1 other study(ies) available for quinoline and tas-116
| Article | Year |
|---|---|
Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Drug Screening Assays, Antitumor; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Molecular Conformation; Molecular Dynamics Simulation; Neoplasms; Pyrazoles; Quinolines; Recombinant Proteins; Solubility; Structure-Activity Relationship | 2019 |